Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Bladder cancer
Trial Type:  Treatment
Results 1-25 of 82 for your search:
Start Over
Transurethral Resection of Bladder Tumors Using PK Button Vaporization Electrode or Monopolar Loop Electrocautery in Treating Patients with Bladder Cancer
Phase: Phase IV
Type: Treatment
Age: 18 to 89
Trial IDs: WCI2119-11, NCI-2013-00065, IRB00053735, NCT01567462
Standard or Extended Pelvic Lymphadenectomy in Treating Patients Undergoing Surgery for Invasive Bladder Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: S1011, NCI-2011-02604, CDR0000686574, SWOG-S1011, NCT01224665
A Study of Atezolizumab Compared With Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer [IMvigor211]
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: GO29294, NCI-2015-00200, 2014-003231-19, NCT02302807
Safety and Efficacy of CG0070 Oncolytic Virus Regimen for High Grade Non-Muscle Invasive Bladder Cancer After BCG Failure
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: BOND 2 version 3.5, NCI-2015-01830, BOND 2 version 3.4, NCT02365818
A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15679, NCI-2015-02085, 2014-003655-66, I4T-MC-JVDC, NCT02426125
Vicinium Treatment for Subjects With Non-muscle Invasive Bladder Cancer Previously Treated With BCG
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: VB4-845-02-IIIA, NCI-2015-01369, NCT02449239
A Phase III Study of Atezolizumab Treatment Versus Observation as Adjuvant Therapy in Patients With PD-L1 Positive, High Risk Muscle Invasive Bladder Cancer After Cystectomy [IMvigor010]
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: WO29636, NCI-2015-01334, 2014-005603-25, NCT02450331
Study of MEDI4736 With or Without Tremelimumab Versus Standard of Care Chemotherapy in Bladder Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: D419BC00001, NCI-2015-02054, NCT02516241
A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: BBI608-201, NCI-2014-01566, NCT01325441
A Study of ALT-801 in Patients With Bacillus Calmette-Guerin (BCG) Failure Non-Muscle Invasive Bladder Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CA-ALT-801-01-12, NCI-2013-00693, NCT01625260
A Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab in Subjects With Advanced or Metastatic Solid Tumors
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CA209-032, NCI-2013-02337, 2013-002844-10, NCT01928394
Sirolimus, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients with Bladder Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 8027, NCI-2013-01614, NCT01938573
HuMax®-TF-ADC Safety Study in Patients With Solid Tumors
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: GEN701, NCI-2014-01166, NCT02001623
Phase 1/2 Study of ABI-009 in Nonmuscle Invasive Bladder Cancer
Phase: Phase II, Phase I
Type: Treatment
Age: Over 18
Trial IDs: BC001, NCI-2015-01102, 1R42CA171552-01, NCT02009332
A Phase 1/2 Study of HS-410 in Patients With Non-Muscle Invasive Bladder Cancer After TURBT
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: HS410-101, NCI-2014-01420, NCT02010203
A Study of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CA-ALT-803-01-14, NCI-2014-02463, NCT02138734
Neoadjuvant Pembrolizumab in Combination With Gemcitabine Therapy in Cis-eligible/Ineligible UCC Subjects
Phase: Phase II, Phase I
Type: Treatment
Age: Over 18
Trial IDs: HCRN GU14-188, NCI-2015-01257, NCT02365766
A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: PLX108-14, NCI-2015-01614, KEYNOTE-103, NCT02452424
A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CDX1127-06, NCI-2015-02086, NCT02543645
BCG Intravesical Solution and Sunitinib Malate in Treating Patients With Bladder Cancer
Phase: Phase II
Type: Treatment
Age: Over 18
Trial IDs: UMCC 2008.086, NCI-2011-03616, NCT00794950
Radiation Therapy and Cisplatin or Mitomycin and Fluorouracil in Treating Patients with Non-Muscle Invasive Stage I Bladder Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: RTOG 0926, NCI-2011-01974, 13-C-0175, CDR0000654727, PRTOG-0926_A05PAMDREVW01, NCT00981656
Start Over